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Mesenchymal stromal cells (MSCs) have recently emerged as promising candidates for cell-
based immunotherapy in solid organ transplantation (SOT). In addition to immune modu-
lation,MSCs possess proreparative properties and preclinical studies indicate thatMSCs have
the capacity to prolong graft survival and in some cases induce tolerance. Currently, the
application of MSCs in SOT is being evaluated in phase I/II clinical trials. Whereas the
mechanisms of action used by MSC immunomodulation have been somewhat elucidated
in vitro, the data from preclinical transplant models have been unclear. Furthermore, the
optimal timing, dose, and route of administration remain to be elucidated. Importantly,MSCs
have the ability to sense their environment, which may influence their function. In this
article, we discuss the impact of the local microenvironment on MSCs and the mechanisms
of MSC immunomodulation in the setting of SOT.
Mesenchymal stromal cells (MSCs) are asubpopulation of multipotent cells origi-
nally identified in the bone marrow (Frieden-
stein et al. 1976). MSCs are characterized by
their fibroblast-like appearance, colony forming
unit capacity, and their rapid adherence to tis-
sue culture plastic. Although MSCs are relative-
ly easy to isolate, culture, and expand (from a
number of tissues), the lack of a unique marker
to identify MSCs has impacted the advance-
ment of this research field as difficulties arise
in comparing data using different MSC popu-
lations. In 2006, the International Society for
Cellular Therapy proposed a set of phenotypic
and functional criteria to define MSCs (Domi-
nici et al. 2006), however, the discovery of new
markers that specifically identify MSCs are ea-
gerly awaited. MSCs have the capacity to differ-
entiate into adipocytes, chondrocytes, and os-
teoblasts in vitro and in vivo (Pittenger et al.
1999). Based on the differentiation potential
of MSCs, initially studies focused on the regen-
erative capacity of these cells (Mahmood et al.
2003; Murphy et al. 2003); however, over time,
it became clear that MSCs mediated their ef-
fects predominantly through the production
of trophic factors (Caplan and Dennis 2006;
Prockop 2009). Indeed, some of these trophic
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factors facilitate MSC modulation of immune
responses.
One of the first reports describing MSC im-
munosuppressive capacity was in fact a trans-
plant model that showed that allogeneic (donor
derived)MSCsprolongedallogeneic (donorand
third-party-derived) skin graft survival (Bar-
tholomew et al. 2002). Around the same time,
Di Nicola et al. (2002) showed thatMSCsmedi-
ated their suppressive effect through secretion of
soluble factors. A significant body of data now
supports an immunosuppressive capacity for
MSCs both in vitro and in vivo. At the outset,
studies focused primarily on MSC suppression
of the adaptive immune response showing that
MSCs can directly inhibit T-cell function, shift
the T-helper lymphocyte balance, induce T-cell
apoptosis, and induce functional regulatory T
cells (Treg) (Kong et al. 2009; Ge et al. 2010;
Akiyama et al. 2012). With respect to B cells,
the available data are sparse and in some cases
contradictory, but some studies suggest that
MSCs can also suppress B-cell proliferation
and function (Comoli et al. 2008). Recent find-
ings convincingly show that MSCs modulate
multiple components of the innate immune sys-
tem including complement, toll-like receptor
(TLR) signaling, macrophages, dendritic cells
neutrophils, mast cells, and natural killer cells
(Spaggiari et al. 2006; English et al. 2008; Kim
and Hematti 2009; Nemeth et al. 2009; Cutler
et al. 2010;Choi et al. 2011).Therapeutic efficacy
of MSC anti-inflammatory effects has been es-
tablished in a number of preclinical models in-
cluding graft versus host disease, sepsis, inflam-
matoryboweldisease, andallergic airwaydisease
(Polchert et al. 2008; Ren et al. 2008; Nemeth
et al. 2009;KavanaghandMahon2011;Akiyama
et al. 2012). In the case of solid organ transplan-
tation (SOT), MSCs exert their effects on two
fronts through attenuation of ischemia reperfu-
sion injury (Liu et al. 2012a) and through the
prevention of allograft rejection (Casiraghi et al.
2008; Ding et al. 2009; Ge et al. 2010).Moreover,
in some cases, MSC induce a state of tolerance
(Geet al. 2010;Casiraghi et al. 2012).The invitro
immunosuppressive capacity, combined with
the proven therapeutic efficacy of MSCs in pre-
clinical models, has paved the way for MSCs in
clinical application. Further evidence of a pro-
tective role for MSCs in preclinical models of
organ transplantation in combination with the
reported safety of MSCs in clinical trials has
prompted the evaluation of safety and efficacy
of MSCs in SOT (Tan et al. 2012). Herein, we
will discuss the underlyingmechanisms ofMSC
immunomodulation in the context of ische-
mia reperfusion injury, prevention of allogeneic
graft rejection, and induction of tolerance.
REJECTION
Mechanisms of Transplantation Rejection
Despite the significant achievements accom-
plished during the past 60 years in SOT, rejec-
tion remains the greatest barrier (Wood and
Goto 2012; Wood et al. 2012). Whereas, the
advent of immunosuppressive drugs has facili-
tated improved outcomes in graft survival and
long term function, the toxicity and associated
complications of nonspecific immunosuppres-
sion are substantial limiting factors (Halloran
2004). Thus, there is a significant unmet need
for nontoxic immunosuppressive therapies.
The immune response to an allograft is an
ongoing process involving both innate and
adaptive components starting from themoment
of reperfusion. In fact, the tissue injury asso-
ciated with organ retrieval (ischemic injury)
initiates the production of damage-associated
molecular patterns (DAMPs) and subsequent
activation of the complement system and in-
nate immune cells (macrophages and neutro-
phils) through pathogen recognition receptors
(PRRs) (Eltzschig and Eckle 2011) after reper-
fusion and initiates a local inflammatory en-
vironment. Activation of the innate immune
response orchestrates the adaptive immune re-
sponse. Although, graft rejection is multifac-
torial, alloantigen specific induction of T-cell
proliferation and activation of T-cell effector
functions is the major player in graft destruc-
tion. Antibody mediated rejection is triggered
by alloantibody binding and complement ac-
tivation and also significantly contributes to
graft loss. Here, we discuss the effect of MSC
on ischemia reperfusion injury and innate and
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adaptive components in the context of solid or-
gan transplantation.
ISCHEMIA REPERFUSION INJURY
Effect of Mesenchymal Stromal Cells on
Ischemia Reperfusion Injury
Ischemia reperfusion injury causes sterile in-
flammation and results in the production of
a number of DAMPs including necrotic cells,
cellular debris, heat shock proteins (HSPs), and
high mobility group protein box-1 (HMGB-
1) (Eltzschig and Eckle 2011). DAMPs acti-
vate PPRs such as TLRs, C-type lectin receptors,
nucleotide-binding oligomerization domain
(NOD) and NOD-like receptors, receptor for
advanced glycation endproducts (RAGE), and
retinoic acid inducible gene-I receptors. Signal-
ing through these receptors results in activation
of the inflammasome(Ogura et al. 2006) and the
complement system, upregulating gene tran-
scription and production of micro-RNAs (Eltz-
schig and Eckle 2011) involved in the inflamma-
tory response. Together, these factors lead to the
production of proinflammatory cytokines, the
activation of platelets and endothelial cells, tis-
sue hypoxia, and the recruitment of innate and
eventually adaptive immune cells (Eltzschig and
Eckle 2011).
MSCs are known to express a number of
PRRs, including TLR1-9 (Pevsner-Fischer et al.
2007; Tomchuck et al. 2008; Opitz et al. 2009;
Romieu-Mourez et al. 2009), NOD receptors
(Kim et al. 2010; Sioud et al. 2010), and RAGE
(Kume et al. 2005). These receptors are func-
tionally active on MSCs, and binding to their
respective ligands leads to alterations in MSC
functions. For example, stimulation of NOD-
like receptors on MSC leads to the production
of interleukin (IL)-8 and vascular endothelial
growth factor (Kim et al. 2010; Sioud et al.
2010). HMGB-1 signaling through RAGE in-
duced MSC migration and inhibited MSC pro-
duction of indoleamine 2,3-dioxygenase (IDO)
(Lotfi et al. 2011). TLR3 and TLR4 activation of
MSCs resulted in differential effects with TLR4
priming inducing a proinflammatory pheno-
type and secretion of IL-6, IL-8, and transform-
ing growth factor b (TGF-b), whereas TLR3
priming induced anti-inflammatoryMSCs pro-
ducing IDO, prostaglandin E-2 (PGE-2), IL-4,
and IL-1RA (Waterman et al. 2010). In regard to
MSC immunosuppressive function, TLR3 and
TLR4 enhanced MSC immunosuppression in
vitro through IDO induction via IFN-b and
protein kinase R signaling (Opitz et al. 2009).
In addition, TLR2 but not NOD-1 activation of
humanMSCs resulted in the upregulation of the
immune suppressive protein galectin-3 (Sioud
et al. 2010). In contrast, Liotta et al. (2008)
showed that TLR3 and TLR4 ligand binding at-
tenuated MSC immunosuppressive effects. It is
clear that MSCs are receptive to environmental
cues that may be present during ischemia reper-
fusion injury, however, further research is re-
quired to understand how these DAMPs effect
MSCs and whether or not they play a role in
determining the function of MSCs.
MSCs are also responsive to complement
and migrate in response to C1q, C3a, and C5a
(Schraufstatter et al. 2009; Qiu et al. 2012), and
high levels of C3 activation correlate with en-
hanced immunosuppressive capacity of MSCs
(Moll et al. 2011). Importantly, MSCs express
CD59, a complement regulatory protein, and
also release complement factor H that pro-
tects them from complement lysis (Tu et al.
2010; Moll et al. 2011). In addition, stimulation
through C3aR and C5aR protect MSCs from
oxidative damage (Schraufstatter et al. 2009)
and MSCs produce a number of antioxidants
including hemeoxygenase-1 and superoxide dis-
mutase (Kemp et al. 2010; Mougiakakos et al.
2011), and have been shown to suppress oxida-
tive stress and inflammation in ischemia reper-
fusion injury models in vivo (Chen et al. 2011,
2012; Sun et al. 2011; Du et al. 2012). The exact
mechanisms of action are unclear; however,
MSC protection in these models was associated
with increased expression of IL-10, heme oxy-
genase-1 (HO-1), and hepatocyte growth fac-
tor, decreased expression of the proinflamma-
tory cytokines IL-1b, TNF-a, and interferon g
(IFN-g), reduced reactive oxygen species, re-
duced apoptosis and decreased numbers of
activated T cells, and infiltrating immune cells
(Hara et al. 2011; Sun et al. 2011; Chen et al.
2012; Du et al. 2012).
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MSC derived microvesicles combined with
soluble factors have been shown to protect
against ischemia reperfusion induced acute
and chronic kidney injury through inhibition
of apoptosis and stimulation of tubular epithe-
lial-cell proliferation (Gatti et al. 2011). Impor-
tantly, a protective effect of MSCs in ischemia
reperfusion transplant models has been re-
ported. Administration of MSCs reduced intra-
graft inflammatory gene expression and recruit-
ment of antigen presenting cells into the al-
lograft in a prolonged cold ischemic kidney
transplant model (Hara et al. 2011) and provid-
ed long-term protection from chronic allograft
nephropathy (Franquesa et al. 2012a). Ischemia
reperfusion also plays a key role in the recruit-
ment of MSCs to transplanted organs (Casira-
ghi et al. 2012). MSC recruitment mediated
by ischemia reperfusion injury in combination
with an ongoing alloreactive response leads to
premature graft dysfunction and fails to prolong
graft survival (Casiraghi et al. 2012). This study
showed that althoughMSCs administered post-
transplant promoted neutrophil infiltration and
complement deposition, infusion of MSCs pre-
transplant induced significant allograft survival
through a Treg dependent mechanism (Fig. 1)
(Casiraghi et al. 2012). The key observation of
this study is that MSCs infused pretransplant
localize in the lymphoid organs whereas MSC
administered posttransplant are recruited to the
graft (syngeneic or allogeneic). Overall, it seems
that MSCs can exert protective effects in ische-
mic reperfusion injuries through anti-inflam-
matory and paracrine factors and this likely
plays an important part in MSC enhancement
of allograft survival. However, there is still a lot
to learn with regard to the effect of the ischemic
environment on MSC functions and how this
might impactMSC therapy in solid organ trans-
plantation.
TOLERANCE
Mesenchymal Stromal Cell Modulation of
Macrophages
Macrophages and neutrophils are generally the
first innate immune cells to infiltrate the graft
postischemia reperfusion injury. Whereas neu-
trophils are present only in the graft during in-
flammatory episodes, macrophages are present
throughout the life of the graft, infiltrating in
response to ischemia reperfusion injury, and
maintained in reduced numbers after resolu-
tion of tissue injury in the absence of rejection.
Neutrophils and macrophages have been shown
to play a role in graft rejection through tissue
damage induced by effector function, produc-
tion of proinflammatory cytokines, and acti-
vation of antigen specific T cells (Wyburn et al.
2005). On the other hand, macrophages are
also known to play a role in tissue repair and
can be repolarized from pro to anti-inflam-
matory (Sica and Mantovani 2012). Although
it has not been shown in a SOT setting, MSCs
have the capacity to re-educate monocytes/
macrophages. MSCs induce alternatively acti-
vated macrophages down-regulating the pro-
duction of TNF-a, IL-1a, IL-6, and IL-12p70,
and increasing the production of IL-10 and en-
hancing phagocytic activity (Kim and Hematti
2009;Nemeth et al. 2009;Cutler et al. 2010;Choi
et al. 2011) through production of IDO and
PGE-2 (Maggini et al. 2010; Francois et al. 2012).
Two important studies build a picture of
howMSCs orchestratemacrophage polarisation
and the influence the local microenvironment
has on that process. Nemeth and colleagues
show that MSCs ameliorate sepsis through al-
ternative activation of macrophages, showing
that lipopolysaccharide (LPS) and TNF-a acti-
vate TLR4 and tumor necrosis factor receptor 1
on MSCs to activate NF-kB signaling. This, in
turn, leads to the expression of cyclooxygenase
(COX)-2 and synthesis of PGE-2 by MSCs that
bind E-prostanoid 2/4 (EP2/EP4) receptors on
macrophages resulting in increased production
of IL-10 and facilitating the resolution of in-
flammation (Nemeth et al. 2009). In the second
study, Prockop’s group used a zymosan induced
peritonitis model to show that MSCs exerted
anti-inflammatory effects through the produc-
tion of tumor necrosis factor a (TNF-a)-in-
duced protein 6 (TSG-6), which subsequently
limits TLR2/NF-kB signaling through direct
interaction with CD44 expressed on the ma-
crophage to initiate a negative feedback loop
K. English and K.J. Wood
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inhibiting the inflammatory response (Choi
et al. 2011). Although MSC secretion of TSG-
6 has been implicated in corneal allograft sur-
vival (Oh et al. 2012), it remains to be deter-
mined whether or not MSC derived TSG-6
can modulate macrophages in this setting.
On thewhole,microenvironmental cues present
at the site of MSC activation seem to determine
the particular mechanism of actions deployed
by MSCs in modulating the immune response
and resolving inflammation.
Mesenchymal Stromal Cell Modulation of
Dendritic Cells
Dendritic cells (DCs) are sentinel cells and
as such, present alloantigens activating anti-
gen specific T cells. Both donor and recipient
Ischemia
reperfusion injury
DAMPs
(HMGB-1, HSPs)
ROS
(C3, C1q, C5a)
Macrophage
NeutrophillTransplanted
organ
Proinflammatory NOD RAGE TLRs Anti-inflammatory
TregTol DC
Graft
acceptance
IDO
Neutrophil
recruitment IL-6
IL-8 Serum
creatinine
Accelerated
graft rejection
C3
TNF-α
TNF-α
TGF-β
PGE-2
IL-4
IL-1RA
TSG-6
IFN-γ
IL-1β
ROS
Apoptosis
MSC administration
Timing, dose, route
MSC
Figure 1. Influence of ischemia reperfusion injury on MSC function. Ischemia reperfusion injury (associated
with organ retrieval) leads to the production of DAMPs including HMGB-1 and HSPs among others.
Signaling through PRRs including TLRs, NOD receptors, and RAGE results in the activation of the comple-
ment system, recruitment of innate immune cells (neutrophils and macrophages), and the production of
reactive oxygen species (ROS). Depending on the timing, dose, and route of administration, MSC given to
patients in the context of SOT may encounter an ischemia reperfusion microenvironment. MSCs express a
number of PRRs including NOD, RAGE, and TLRs, and activation of these receptors through DAMPs like
HMGB-1 and HSPs may determine MSC function. Signaling through RAGE, NOD-like receptors, or TLR4 on
MSC may lead to the promotion of a proinflammatory environment leading to the production of the pro-
inflammatory cytokines IL-6, IL-8, and TNF-a, neutrophil recruitment, and complement deposition resulting
in elevated serum creatinine and accelerated graft rejection. Alternatively, activation of TLR3 on MSC may
induce an anti-inflammatory milieu, reducing the production of proinflammatory cytokines (IL-1b, TNF-a,
and IFN-g), decreasing ROS and apoptosis, and generating tolerogenic dendritic cells and Treg facilitating
graft acceptance.
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DCs play a critical role triggering graft rejection
through the direct, indirect, or semi-direct path-
ways of allorecognition (Wood and Goto 2012).
MSCs can interfere with the key features of
DC function: migration, maturation, and anti-
gen presentation (English et al. 2008), and me-
diate these effects through down-regulation of
DC maturation markers including major histo-
compatibility complex (MHC) class II, CD40,
CD80, and CD86 (Nauta et al. 2006a; Djouad
et al. 2007; Li et al. 2008b; Zhang et al. 2009),
and modulation of the lymph node homing
chemokine receptor CCR7 in vitro (English
et al. 2008) and in vivo (Chiesa et al. 2011).
The soluble factor IL-6 produced by MSCs has
been shown to be involved in down-regulation
of maturation markers (Nauta et al. 2006a;
Djouad et al. 2007; English et al. 2008), whereas
contact-dependent Notch signaling but not IL-
6 was shown to be required for DC modulation
in another study (Li et al. 2008b). Further sup-
port of a role forNotch signaling in this scenario
has been put forward by Zhang and colleagues
(2009) showing contact-dependent Jagged-2 (a
Notch ligand) signaling in the generation of reg-
ulatory DC. In the context of SOT, MSCs have
been shown to block DC maturation and func-
tion in a kidney allograft model (Ge et al. 2010);
however, the exactmechanismsused byMSCs to
achieve this effect remains to be elucidated.
Analogous to the effects of MSCs on mac-
rophage polarization, MSCs can also promote
the generation of tolerogenic DCs (Li et al.
2008a; Ge et al. 2009; Spaggiari et al. 2009;
Zhang et al. 2009; Liu et al. 2012b) producing
anti-inflammatory cytokines and displaying en-
hanced phagocytic activity (Zhang et al. 2009;
Liu et al. 2012b) typical of tolerogenic DCs.
MSC educated DCs have the capacity to sup-
press alloreactive responses and prolong islet
allograft survival (Huang et al. 2010) and to
induce a state of tolerance in the context of
SOT (cardiac allograft) in the presence of low
dose immunosuppression (Ge et al. 2009).
The mechanisms of action mediated by
MSCs in the generation of tolerogenic DCs are
likely influenced by the context in which MSCs
see DCs. The key mediator in MSC modulation
of DC maturation is IL-6 (Nauta et al. 2006a;
Djouad et al. 2007; English et al. 2008), however,
the mechanism involved in MSC promotion of
tolerogenic DCs has been less clear. Other stud-
ies have shown a central role for PGE-2 (Spag-
giari et al. 2009) and cell contact-dependent ac-
tivation of the Notch signaling pathway (Li et al.
2008b; Zhang et al. 2009), but not IL-6 (Li et al.
2008b; Spaggiari et al. 2009) inMSC generation
of tolerogenic DCs. Further evidence of a con-
tact-dependent mechanism involving activa-
tion of AKTand impaired NF-kB signaling has
been proposed (Chiesa et al. 2011). Finally, it
has been shown that mouse embryonic fibro-
blast derived MSCs generate a novel population
of IL-10 dependent tolerogenic DCs through an
IL-10 activated SOCS3 dependent mechanism
(Liu et al. 2012b).MSC induction of tolerogenic
DCs is a key mechanism involved in MSCmod-
ulation of immune responses; however, signifi-
cant gaps in our understanding of exactly how
MSCs promote the generation of tolerogenic
DCs remain.
Mesenchymal Stromal Cell Suppression
of Allogeneic T-Cell Responses in
Transplantation Rejection
Allogeneic T-cell proliferation and activation
are prerequisites for allograft rejection and in-
duction of tolerance in allogeneic organ trans-
plantation is usually associated with Treg (Issa
et al. 2011; Wood et al. 2012). A large body of
data convincingly show that autologous and
allogeneic MSCs modulate T-cell proliferation,
activation, and function both in vitro and in
vivo (Di Nicola et al. 2002; Glennie et al. 2005;
English et al. 2007; Asari et al. 2009; Ding et al.
2009; English and Mahon 2011). Moreover, in
vitro assays have also confirmed the capacity for
MSCs to inhibit Th17 cell differentiation (Duffy
et al. 2011; Tatara et al. 2011) or to shift the T
helper cell balance in favor of a more anti-in-
flammatory phenotype (Batten et al. 2006; Bai
et al. 2009; English et al. 2009; Fiorina et al.
2009; Ghannam et al. 2010). The mechanisms
used by MSCs in mediating these effects vary
between in vitro and in vivo models. However,
manyof these effects aremediated through solu-
ble factors secreted by MSCs (English 2013).
K. English and K.J. Wood
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IDO and PGE-2 have been implicated in MSC
inhibition of Th17 differentiation (Duffy et al.
2011; Tatara et al. 2011). In the case of PGE-2,
the steps involved in the process require contact-
dependent COX-2 induction of PGE-2 and di-
rect inhibition through EP4 (Duffy et al. 2011).
MSCs can also mediate this effect through sup-
pressing the Th17 transcription factor RORgt
and upregulating Foxp3 to induce a Treg phe-
notype producing IL-10 (Ghannam et al. 2010).
MSC derived TGF-b has been shown to play a
partial role in shifting the balance of Th1/Th2/
Th17 and Treg in an autoimmune diseasemodel
(Kong et al. 2009).
With regard to SOT, MSCs impaired allo-
reactive T-cell responses (Casiraghi et al. 2008,
2012;Ge et al. 2010) and inhibited themigration
of activatedT cells into the allograft (Eggenhofer
et al. 2011b; Hara et al. 2011; Franquesa et al.
2012a). In particular, matrix metalloproteinase
(MMP)2 andMMP9 secreted byMSCs facilitat-
ed cleavage of CD25 expressed on CD4þ T cells
inhibiting alloantigen driven proliferation and
preventing islet allograft rejection (Ding et al.
2009). Other evidence suggests that MSC de-
rived MMPs also cleave CC chemokine ligand
(CCL2), which subsequently inhibits Th17 acti-
vation via a STAT3 dependent pathway (Rafei
et al. 2009). In addition, MSCs mediated their
effects in part through shifting the balance of T
helper 1 cell phenotype to a more anti-inflam-
matory Th2 phenotpye producing IL-4 and IL-
10 (Ge et al. 2010; Jia et al. 2012). Importantly,
MSCs also have the capacity to expandor induce
Treg in the setting of SOT (Casiraghi et al. 2008,
2012; Wang et al. 2009; Jia et al. 2012) and in
some cases to generate a state of Treg-dependent
tolerance (Ge et al. 2010; Casiraghi et al. 2012).
Both of these studies elegantly show the impor-
tance of Treg in MSC induced tolerance using
Treg depletion studies. Apart from the study by
Ge et al. (2010), which identifies an important
role for MSC derived IDO in the generation of
Treg, the mechanisms of action mediated by
MSCs remain to be elucidated. In vitro, the fac-
tors required for MSC induction of Treg are
thought to involve cell contact, PGE-2, and
TGF-b (English et al. 2009). Further evidence
for a contact-dependent role was provided by
Selmani and colleagues, showing that cell con-
tact-dependent production of HLA-G5 was re-
quired for the expansion of Treg (Selmani et al.
2008). Invivo,MSCderivedTGF-bwas required
for the generation of antigen specific Treg and
overall, TGF-b seems to be the major soluble
factor involved in MSC promotion of Treg in
vivo (Zhao et al. 2008; Kong et al. 2009; Nemeth
et al. 2010; Akiyama et al. 2012). MSC genera-
tion of Treg involves a number of different steps
that are dependent on the specific environment
or diseasemodel. For example, Nemeth and col-
leagues (2010) showed thatMSCs exposed to IL-
4 and IL-13 (typically produced in allergic envi-
ronment) produced TGF-b through an IL-4R/
STAT6 dependent pathway. Alternatively, MSCs
may induce Treg indirectly throughmodulation
of innate immune cells. A study performed by
Akiyama et al. examining the effect of MSCs
in a mouse model of dextran sodium sulfate-
induced colitis, unravelled a complex course
of events that ultimately led to the expansion
of Treg. Specifically, MSCs induced T effector
cell apoptosis through FAS/FASL facilitated by
MSCMCP-1 chemoattraction of T cells. Subse-
quently,macrophages produceTGF-b following
phagocytosis of the apoptotic cell debris result-
ing in the expansion of Treg (Akiyama et al.
2012).
INTERACTION OF MESENCHYMAL
STROMAL CELLS WITH ALLOREACTIVE
B CELL RESPONSES
The triggering of antibody mediated rejection
by alloantibody binding and complement acti-
vation is increasingly associated with graft loss
(Wood and Goto 2012). The reported effects
of MSCs on B-cell activation, proliferation,
and function have been variable and in some
cases contradictory. MSCs have been shown to
inhibit B-cell proliferation (Augello et al. 2005;
Corcione et al. 2006; Asari et al. 2009; Schena
et al. 2010) and immunoglobulin (Ig) pro-
duction (Corcione et al. 2006; Comoli et al.
2008; Rafei et al. 2008) in vitro. The mecha-
nisms of action involve contact-dependent fac-
tors (Schena et al. 2010) including programmed
death-1 [PD-1]/programmeddeath-ligand [PD-
MSCs in Transplantation
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L1]/PD-L2 (Augello et al. 2005) as well as solu-
ble factors like MMP cleaved CCL2 (Rafei et al.
2008). MSC inhibition of plasma cells induced
by LPS or plasmacytoid DCs was shown to be
mediated through extracellular signal-related
kinases (ERK) 1/2 and phosphorylation of
p38 (Tabera et al. 2008; Asari et al. 2009). More-
over, MSCs induced cell cycle arrest in B cells
(Corcione et al. 2006), and particularly under
highly proliferative conditions (Traggiai et al.
2008). In contrast, MSCs also have the capacity
to promote B-cell proliferation and survival
(Tabera et al. 2008; Traggiai et al. 2008; Youd
et al. 2010) and enhance Ig production (Ras-
musson et al. 2007; Youd et al. 2010). Consid-
erable variations are reported in these findings
withMSCs increasing IgMbut not IgAor IgG in
another study (Traggiai et al. 2008) with differ-
ences in the mechanisms involved (contact-de-
pendent versus soluble factors) depending on
the source of B cells (purified versus peripheral
blood mononuclear cells or mononuclear cells)
(Rasmusson et al. 2007) and the ratio of MSCs
to B cells in co-cultures (Franquesa et al. 2012b).
These differencesmay well be resolved by ensur-
ing purity of B cells (excluding T-cell help) and
by further understanding the effect that TLR
ligands (LPS, cytosine phosphodiester guanine,
polyinosinic:polycytidylic acid) have on MSC
activation and function. The effect of MSCs
has also been examined in the B cell driven pa-
thology systemic lupus erythematosus (SLE)
both in mouse models and in patient samples.
MSC enhanced survival and reduced serum
creatinine, blood urea nitrogen, proteinuria,
C3 deposition, and decreased circulating dou-
ble-stranded deoxyribonucleic acid (dsDNA)
antibodies as well as antigen specific IgM and
IgG secretion (Zhou et al. 2008; Asari et al. 2009;
Choi et al. 2011). In contrast, Schena et al. (2010)
reported no effect of MSCs on survival, pro-
teinuria, or dsDNA antibodies. Furthermore,
MSCs were shown to negatively impact SLE
through enhancing pathology, autoantibody
production, and proteinuria (Youd et al. 2010).
In the setting of SOT, much of the focus has
been on the effect of MSCs on T cells (discussed
above), and to our knowledge, no study has
rigorously examined the impact of MSC on al-
loreactive B cells. Nonetheless, there are reports
that suggest that MSCs reduce intragraft IgG
deposits as well as circulating donor specif-
ic antibodies (Ge et al. 2009; Franquesa et al.
2012a) providing protection from injury (Fran-
quesa et al. 2012a) and inducing allograft toler-
ance in the presence of immunosuppression
(Ge et al. 2009). Notably, failure of MSCs to
prolong allograft survival has been associated
with MSC promotion of intragraft B cell infil-
tration (Seifert et al. 2012), and although ad-
ministration of donor MSCs posttransplant
lead to sensitization and premature graft dys-
function, this was not thought to be associated
with antibody mediated humoral rejection (Ca-
siraghi et al. 2012). Rather, syngeneic MSCs ad-
ministered posttransplant (but not pretrans-
plant) localized in the transplanted kidney in
response to ischemia reperfusion injury and
subsequently produced IL-6 and TNF-a pro-
moting a proinflammatory environment facili-
tating neutrophil infiltration and C3 deposition
(Casiraghi et al. 2012). These studies highlight
the significant gap in our understanding of the
effect of the microenvironment onMSC activa-
tion and function and particularly the effect this
has on how MSCs see B cells and vice versa.
Immunogenicity of Allogeneic Mesenchymal
Stromal Cells
Although, allogeneic MSCs were thought to
be immune privileged, evidence now suggests
that allogeneic MSCs are recognized by the in-
nate and adaptive immune system (Griffin et al.
2013). A clear understanding of how recogni-
tion of allogeneic MSCs impacts their capac-
ity for modulating immune responses in vivo
is hampered by the lack of appropriate exper-
imental data measuring antidonor T-cell and
antibody responses to allogeneic MSC. Nev-
ertheless, a small number of studies show that
allogeneic MSC evoke antidonor T-cell and an-
tibody responses in vivo in healthy animals
as well as models of myocardial infarction and
bone marrow transplantation (Eliopoulos et
al. 2005; Beggs et al. 2006; Nauta et al. 2006b;
Badillo et al. 2007; Poncelet et al. 2008; Zangi
et al. 2009; Isakova et al. 2010; Schu et al. 2012).
K. English and K.J. Wood
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In the SOT setting, allogeneic MSC have been
shown to accelerate graft rejection (Inoue et al.
2006; Popp et al. 2008; Renner et al. 2009; Eg-
genhofer et al. 2011a,b; Seifert et al. 2012). In
some cases, accelerated graft rejection was at-
tributed to administration of allogeneic MSC
pretransplant (Eggenhofer et al. 2011b; Seifert
et al. 2012) or syngeneic MSC posttransplant
(Casiraghi et al. 2012). In other cases, allogeneic
or syngeneic MSC were shown to attenuate
immunosuppressive drugs like cyclosporine
A (Inoue et al. 2006). Importantly, allogeneic
MSCs have the capacity to work in synergy
with immunosuppressive drugs including my-
cophenolate mofetil (Eggenhofer et al. 2011a,b)
and rapamycin (Ge et al. 2009), and in these
studies promote graft survival. Perhaps these
studies emphasize the impact that different mi-
croenvironments may have on allogeneic MSC
immunogenicity as well as the immunosuppres-
sive function of both syngeneic and allogeneic
MSCs in vivo. These conflicting reports high-
light the significant need for further research in
this area.
CLINICAL APPLICATION OF
MESENCHYMAL STROMAL CELLS IN
SOLID ORGAN TRANSPLANTATION
The application of MSC therapy in conjunction
with a reduced immunosuppressive regimen is
theoretically very appealing as MSCs not only
promote the resolution of inflammation and
enhance graft repair, but also may facilitate the
induction of tolerance. Based on the safety and
efficacy data generated in preclinical models
and clinical trials utilizing MSC therapy for
acute graft versus host disease (Casiraghi et al.
2008; LeBlanc et al. 2008; Ge et al. 2010), MSC
therapy is currently being evaluated in SOT
(Hoogduijn et al. 2010). Perico and colleagues
(2011) provided the first report on MSCs in
kidney transplant patients in a pilot study ex-
amining safety and feasibility. Culture expanded
autologous bone marrow derived MSCs (1.7 
106–2.0  106/kg body weight) were adminis-
tered intravenously on day 7 postkidney (living
donor) transplant in addition to T-cell deple-
tion induction therapy in two patients. This
study reported an increase in serum creatinine
in both patients 7–14 days after MSC infusion.
In addition, a focal inflammatory (granulocyte)
infiltrate was observed in a graft biopsy taken
from one of the patients, but acute graft rejec-
tion was ruled out. Importantly, both patients
maintained stable graft function, which was as-
sociated with decreased memory CD8þ T cells
and increased Treg (Perico et al. 2011). Notably,
similar effects were observed in a mouse mod-
el of kidney allograft transplantation, and this
study elegantly showed the correlation of pre-
mature graft injury with posttransplant (but
not pretransplant) syngeneic MSC infusion
and localization of the MSCs primarily in the
injured graft (Casiraghi et al. 2012). Indeed
these studies may help to resolve the disparate
findings with regard to MSC efficacy in pro-
longing graft survival (Inoue et al. 2006; Popp
et al. 2008; Renner et al. 2009; Eggenhofer et al.
2011a,b; Seifert et al. 2012). This highlights the
importance of timing of MSC administration
and the requirement for a better understanding
of the influence of the transplanted graft micro-
environment (ischemia reperfusion, for exam-
ple) onMSC function (Fig. 1). A large random-
ized controlled trial (106 patients over three
arms) investigating the safety and efficacy of
autologous bonemarrow derivedMSCs (in kid-
ney transplantation) in combination with stan-
dard dose calcineurin inhibitors (CNI), or low
dose CNI were compared with control groups
receiving anti-IL-2 receptor antibody therapy
in combination with standard dose CNI (Tan
et al. 2012). This trial showed safety and effi-
cacy with decreased incidence of acute rejec-
tion and glucocorticoid-resistant rejection, and
increased estimated glomerular filtration rate
levels and faster recovery of renal function in
the first month post transplant as well as better
estimated renal function at year 1. In addition,
MSC treated groups revealed significantly re-
duced risk of opportunistic infections than the
control group (Tan et al. 2012). Importantly, this
large randomized controlled trial did not ob-
serve increased creatinine levels in MSC treated
patients and thismay be associatedwith the dose
and/or timing (1–2  106 on day 0 and day 14
versus 1.7–2  106 on day 7 posttransplant) of
MSCs in Transplantation
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MSC administration or with differences in im-
munosuppressive regimen (Perico et al. 2011;
Tan et al. 2012). These are important factors
that may significantly impact MSC efficacy in
SOTand require careful consideration.
CONCLUDING REMARKS
Although the capacity for MSCs to modulate
immune responses in vitro has been undeni-
able, the in vivo immunosuppressive function
of MSCs has, at times, been ambiguous. Over
time it has become clear thatMSCs are receptive
to microenvironmental cues, and indeed evi-
dence has emerged to suggest that the interac-
tions between MSCs and the local environment
are fundamental in determining MSC activa-
tion and function. In vivo models have shown
that MSCs are responsive to ischemia reperfu-
sion injury and can provide protection in this
setting. Moreover, MSCs have the capacity to
prolong graft survival and, indeed, may induce
tolerance. Together, these characteristics make
MSCs an ideal candidate for application in SOT,
and early data from clinical trials suggest that
MSCs are safe and efficacious, but highlight the
gap in our understanding of how exactly MSCs
mediate their protective effects in vivo. To this
end, we must endeavor to fill these gaps and
enhance MSC therapeutic efficacy.
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